Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Dr. Norman Sussman, Chief Medical Officer, and Dr....
DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2022 and provided a corporate update....
DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2022 financial results and host a conference call after the...
DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, will be participating in a panel discussion at the...
DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Dr. WeiQi Lin, Executive Vice President of R&D and Dr....
DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2021 and provided a corporate...
DURECT Corporation (Nasdaq: DRRX) today announced it dosed the first patient in the European Union as part of its AHFIRM randomized, double-blind,...
DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2021 financial results and host a conference...
DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, and Dr....
DURECT Corporation (Nasdaq: DRRX) today announced a licensing agreement granting Innocoll Biotherapeutics plc, a specialty pharmaceutical company and ...
DURECT Corporation (Nasdaq: DRRX) today announced the expansion of its board of directors with the appointment of Peter García, a biopharmaceutical...
DURECT Corporation (Nasdaq: DRRX) announced it will participate in a workshop today at the 5th Annual NASH Summit being held virtually from today...
DURECT Corporation (Nasdaq: DRRX) today announced the presentation of data at the American Association for The Study of Liver Diseases (AASLD) The...
DURECT Corporation (Nasdaq: DRRX) today announced it dosed the first ex-U.S. patient in Australia as part of its AHFIRM randomized, double-blind,...
DURECT Corporation (Nasdaq: DRRX) today announced that Suthat Liangpunsakul, M.D. will present a poster at the American Association for The Study of...
DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2021 and provided a corporate update. "I ...
DURECT Corporation (Nasdaq: DRRX) today announced that it will report its third quarter 2021 financial results and host a conference call after the...
DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr....
DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President, CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman...
DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2021 and provided a corporate update. Q2 2021 ...
DURECT Corporation (Nasdaq: DRRX) today announced that it will report its second quarter 2021 financial results and host a conference call after the...
DURECT Corporation (Nasdaq: DRRX) today announced it will present at the Epigenetic Therapeutic Targets Summit, being held virtually July 13-15, 2021....
DURECT Corporation (Nasdaq: DRRX) today announced the presentation of additional clinical data from a DUR-928 Phase 1b trial in non-alcoholic...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.